主页 > 医药生命 >
【drug-news】专题：文迪雅的2008！
Avandia Slump Makes Glaxo Glum in 2008
February 7, 2008, 9:30 am
Avandia Slump Makes Glaxo Glum in 2008
Posted by Jacob Goldstein
Avandia, the diabetes drug that stirred up trouble last year on a report of incresaed cardiovascular risks, isn’t about to stage a big comeback, GlaxoSmithKline suggested this morning. The company said it expects its 2008 earnings to be down from last year.
“The decline in Avandia sales, together with increased generic competition in the USA, will adversely impact our earnings in 2008,” GSK said in a statement.
Avandia sales were off 25% last year — and the trouble for the drug didn’t start until May. And some 10% of the company’s 2007 sales could be exposed to generic competition this year, Dow Jones Newswires reports.
Glaxo intends to boost sales Avandia once the attention from the media quiets down and the company can resume conversations with doctors, the company’s head of U.S. pharmaceutical operations Chris Viehbacher said Thursday, according to Dow Jones. Doctors haven’t lost faith in the class of diabetic drugs to which Avandia belongs, he said, but he declined to provide a timeline for an Avandia turnaround.
The company has a relatively promising pipeline, but approval of its Cervarix cervical cancer vaccine has been held up in the U.S., even as Merck’s rival vaccine Gardasil has garnered big sales.
For the fourth quarter, net profit was down as the company took a charge tied to a restructuring plan. Avandia Slump Makes Glaxo Glum in 2008
2008，葛兰素因文迪雅而困难重重
Avandia, the diabetes drug that stirred up trouble last year on a report of incresaed cardiovascular risks, isn’t about to stage a big comeback, GlaxoSmithKline suggested this morning. The company said it expects its 2008 earnings to be down from last year.
葛兰素史克公司今早表示该公司治疗糖尿病药物文迪雅不会出现大的情况转变，该药物因去年被报道为会增加心脏血管的风险而引起了一系列的麻烦。公司预计该药08年的销售额会比去年有所下滑。
“The decline in Avandia sales, together with increased generic competition in the USA, will adversely impact our earnings in 2008,” GSK said in a statement.
葛兰素史克公司在一份声明中说，文迪雅销售额下降且美国国内到期专利竞争加剧，都将会对公司的盈利造成不利影响。
Avandia sales were off 25% last year — and the trouble for the drug didn’t start until May. And some 10% of the company’s 2007 sales could be exposed to generic competition this year, Dow Jones Newswires reports.
文迪雅去年销售超过25%——该药到五月份才出现问题，2007年公司10%的销售产品在今年将不再有专利的保护。道琼斯新闻专线报道。
Glaxo intends to boost sales Avandia once the attention from the media quiets down and the company can resume conversations with doctors, the company’s head of U.S. pharmaceutical operations Chris Viehbacher said Thursday, according to Dow Jones. Doctors haven’t lost faith in the class of diabetic drugs to which Avandia belongs, he said, but he declined to provide a timeline for an Avandia turnaround.
道琼斯报道，该公司美国制药业务主管Chris Viehbache星期四说，当媒体关注逐渐平息并且公司可以重新开始与医生进行沟通时，葛兰素会推进文雅迪的销售。他表示，医生并没有对糖尿病类药物文雅迪失去信心。但是他拒绝透漏文雅迪重返市场的时间表。
The company has a relatively promising pipeline, but approval of its Cervarix cervical cancer vaccine has been held up in the U.S., even as Merck’s rival vaccine Gardasil has garnered big sales.
葛兰素有比较先进的信息渠道，但是当它的宫颈癌疫苗Cervarix还没被美国政府批准时，默克的竞争疫苗Gardasil已是赚得盆满钵满。
For the fourth quarter, net profit was down as the company took a charge tied to a restructuring plan.
第四季度，公司由于在重组计划上的开支，净利润有所下滑。 我也来编译一下，互相切磋吧 葛兰素史克问题药在华不退市 在美已致38人死
2007-07-18 09:48 来源：信息时报
糖尿病名药“文迪雅”不良反应上升，厂家坚称该药依然安全
时报讯(记者 何雪峰) 全球制药巨头之一的葛兰素史克生产的糖尿病药物“文迪雅”因不良反应上升而面临退市风险，日前，FDA(美国食品药品监督管理局)不良反应报告显示，该药可能引发心脏病猝死。但葛兰素史克(中国)公共事务部有关人士表示，目前“文迪雅”的使用依然是安全的，因此在中国销售没有受到任何限制。
美国已有38例死亡报告
“目前，在中国还没有发生心脏病猝死的不良反应案例。”昨日，葛兰素史克(中国)公共事务部有关人士在接受记者采访时再三强调。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-05 17:14
医学,生命科学网